Silobreaker.com    Log In
   My Page    Help   
360° SearchNetworkHot SpotsTrends
 
Advanced Search Options >>
Saturday, November 21, 2009 2:27 PM

Last Updated: 03/30/2009 - Able2Act


Fact Sheet for Elan Corporation, plc

Industry: Pharmaceuticals
Country: USA
Contact: Elan Corporation plc,
Treasury Building,
Lower Grand Canal Street,
Dublin 2,
Ireland
Management:
  • G. Kelly Martin ; Carlos Paya ; Menghis Bairu ; Chris Burns ; Nigel Clerkin ; Richard T. Collier ; Shane Cooke ; William Daniel ; Allison Hulme ; Karen Kim : Kathleen Martorano ; Johannes Roebers ; Dale Schenk ; Steven Slaughter ; Mary Stutts ; Ted Yednock
Homepage: http://www.elan.com
Comments:
  • Elan Corporation, plc is a neuroscience-based biotechnology company that is focused on discovering, developing, manufacturing and marketing advanced therapies in neurology, autoimmune diseases, and severe pain.

    On June 5, 2006, Elan and Biogen Idec announced the approval of a supplemental Biologics License Application (sBLA) by the U.S. Food and Drug Administration (FDA) for the reintroduction of TYSABRI® (natalizumab) as a monotherapy treatment for relapsing forms of multiple sclerosis (MS) to slow the progression of disability and reduce the frequency of clinical relapses.

    The FDA granted approval for re-introduction based on the review of TYSABRI clinical trial data; revised labeling with enhanced safety warnings; and a risk management plan (TOUCH Prescribing Program) designed to inform physicians and patients of the benefits and risks of TYSABRI treatment and minimize potential risk of progressive multifocal leukoencephalopathy (PML). Because of the increased risk of PML, TYSABRI monotherapy is generally recommended for patients who have had an inadequate response to, or are unable to tolerate, alternate MS therapies.

    TYSABRI became commercially available in the US in July 2006. Under the TOUCH Prescribing Program, only prescribers, infusion centers, and pharmacies associated with infusion centers registered in the TOUCH program are able to prescribe, infuse or distribute TYSABRI. Elan has contracted with a single distributor, ICS, a division of AmerisourceBergen Specialty Group, and 12 specialty pharmacies: Caremark, CuraScript, PharmaCare, PrecisionRx Specialty Solutions, Medmark, BioScrip, McKesson Specialty, Option Care, Cigna Tel-Drug Specialty Pharmacy, Aetna Specialty Pharmacy, Prescription Solutions, and Accredo NovaFactor. ICS and the 12 specialty pharmacies have been trained on the TOUCH Prescribing Program and are obligated to follow the requirements of the program in order to purchase and distribute TYSABRI to authorized infusion sites and central pharmacies.

    On June 29, 2006, Elan and Biogen Idec announced that they received approval from the European Commission to market TYSABRI® (natalizumab) as a treatment for relapsing remitting multiple sclerosis (MS) to delay the progression of disability and reduce the frequency of relapses. TYSABRI is indicated as a single disease modifying therapy in highly active relapsing remitting MS for patients with high disease activity despite treatment with a beta-interferon or in patients with rapidly evolving severe relapsing remitting MS.

    TYSABRI was launched in Germany, Ireland, U.K. and Sweden in July 2006, and will be launched in other EU countries over the next 12 months.

    On December 28, 2004, the U.S. Food and Drug Administration (FDA) approved PRIALT® (ziconotide intrathecal infusion) for the management of severe chronic pain in patients for whom intrathecal (IT) therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies or IT morphine. PRIALT is approved for use only in the Medtronic SynchroMed® EL, SynchroMed® II Infusion System and CADD-Micro® ambulatory infusion pump.

    On February 22, 2005, the European Commission granted Elan marketing approval for PRIALT? (ziconotide) for the treatment of severe, chronic pain in patients who require intrathecal (IT) analgesia.

    Elan's focus on improving the health of patients suffering from chronic and debilitating conditions is exemplified by its breakthrough research program in Alzheimer's disease, where it has developed three novel therapeutic approaches:

    Immunotherapy In collaboration with Wyeth, this approach targets the clearance of beta-amyloid, the peptide responsible for the build-up of amyloid plaques in the brain

    Beta secretase inhibitors Targets a distinct enzyme associated with the production of beta-amyloid

    Gamma secretase inhibitors Targets a distinct enzyme associated with the production of beta-amyloid
    In neurology, Elan is focused on building upon its breakthrough research and extensive experience in the area of neuropathology-based disorders. In addition to Alzheimer?s disease, Elan is also studying other neurodegenerative diseases, such as Parkinson's disease.

    In autoimmune diseases, Elan?s primary emphasis is studying and developing ways to provide disease-modifying therapies for a wide range of diseases.

    In severe pain, Elan?s research efforts focus on inflammatory and neuropathic pain.

    For more information about Elan?s research and development program, please click here.

    Elan?s marketed products in the the United States include:

    PRIALT® (ziconotide intrathecal infusion)
    AZACTAM® (aztreonam for injection, USP)
    MAXIPIME® (cefepime hydrochloride) for Injection
    For more information about Elan?s products and pipeline, please click here.

    Elan?s Manufacturing business unit develops and manufactures pharmaceutical products for Elan and other customers, providing innovative drug optimization technologies, advanced manufacturing capabilities and global supply chain management services.


    Key Facts
    Locations:
    Athlone, Ireland
    Bermuda
    Dublin, Ireland (headquarters)
    Gainesville, Georgia
    King of Prussia, Pennsylvania
    South San Francisco, California
    Tokyo, Japan
    Employees
    Approximately 1,600 worldwide
Compilation by Silobreaker
Although Silobreaker has relied on what it regards as reliable sources while compiling the content herein, Silobreaker cannot guarantee the accuracy, completeness, integrity or quality of such content and no responsibility is accepted by Silobreaker in respect of such content. Readers must determine for themselves what reliance they should place on the compiled content herein.

Related Stories

First Reported 11/17/2009 - Updated 11/18/2009 - 3 Documents
Air-India Express - Click to view image in its original context
Air-India Express
Air India expects $86.5 million infusion from government
Indian government has "assured support" and promised a INR4 billion ($86.5 million) equity infusion to Air India by January, parent National Aviation Co. of India said yesterday. "Further installments would be tied up to the milestones of savings effected ... [Air Transport World - 11/18/2009]
First Reported 11/15/2009 - Updated 11/15/2009 - 2 Documents
Praful Patel - Click to view image in its original context
Praful Patel
AI to get Rs 8 bln equity infusion
Nov 15 - Civil Aviation Minister Praful Patel on Saturday said ailing state-run carrier Air India will receive equity infusion of 8 billion rupees by December. ... [Reuters India - 11/15/2009]
First Reported 11/14/2009 - Updated 11/14/2009 - 2 Documents (in Health)
Food and Drug Administration - Click to view 360-page
Food and Drug Administration
FDA eyes energy alcohol drinks
U.S. health regulators requested information from nearly 30 makers of caffeinated alcoholic beverages on why they believe their products are safe. ... [Chicago Tribune - 11/14/2009]
First Reported 11/14/2009 - Updated 11/14/2009 - 1 Documents (in Health)
FDA Warns of Contamination in Drugs for Rare Illnesses
Some products used to treat rare, serious, and life-threatening diseases may be contaminated with a number of foreign particles, the FDA cautioned in a newsbrief today.Drugmaker Genzyme reported stainless steel fragments, non-latex rubber from vial stoppers, ... [MedPage Today - 11/14/2009]
First Reported 11/14/2009 - Updated 11/14/2009 - 1 Documents
AI may get 1st tranche of equity infusion by Dec
BELGAUM: Air India is likely to receive the first tranche of equity infusion by December, the Civil Aviation Minister, Mr Praful Patel, said on Saturday. "We will see the first tranche of equity infusion into Air India coming in by December,'' Mr Patel ... [Hindu Business Line - 11/14/2009]
First Reported 10/23/2009 - Updated 10/24/2009 - 13 Documents (in Health)
Elan shares fall by 20pc as drug-linked disease cases rise
Shares in Elan plunged 20pc to ?3.42 in Dublin yesterday after its multiple sclerosis treatment Tysabri was linked to over 20 cases of a potentially fatal brain disease and the European drug watchdog said it was reviewing its use. Elan finished at ?3.42 ... [Irish Independent - 10/24/2009]
First Reported 11/06/2009 - Updated 11/07/2009 - 6 Documents (in Health)
FDA Warns Against Marketing Illegal Flavored Cigarettes
The U.S. Food and Drug Administration is enforcing the flavored cigarette ban provision of the Family Smoking Prevention and Tobacco Control Act (Tobacco Control Act) by issuing several warning letters to companies continuing to sell illegal flavored ... [Red Orbit - 11/07/2009]
First Reported 11/12/2009 - Updated 11/13/2009 - 4 Documents (in Health)
FDA Questions Safety Of Alcoholic Energy Drinks
WASHINGTON — The Food and Drug Administration is challenging makers of alcohol-infused energy drinks to prove their beverages are safe, citing complaints that the products can cause risky behavior and injury. The FDA issued a letter Friday ... [The Huffington Post | Full News Feed - 11/13/2009]
First Reported 11/12/2009 - Updated 11/12/2009 - 3 Documents
Air India to get equity infusion if Rs2k cr saved by March 2010
Based on its performance till the end of this fiscal year, the government would be able to finally take a call at the end of March, civil aviation minister Praful Patel saidPTIEmail Printfont sizeNew Delhi: The government would infuse additional equity ... [Livemint.com - 11/12/2009]
First Reported 11/09/2009 - Updated 11/09/2009 - 2 Documents (in Internet & IT)
Another $1.5B Infusion for Clearwire
It shouldnt come as a surprise: Clearwire, the WiMAX-based wireless network operator, is looking for a $1.5 billion infusion from Sprint and other backers including cable giant Comcast. Clearwire executives, including CEO William Morrow, have been publicly ... [TechNews.AM - 11/09/2009]
First Reported 11/02/2009 - Updated 11/02/2009 - 2 Documents (in Health)
FDA won't accept Merck's application for new drug
Treasury prices tumbled Monday, pushing their yields higher, as stronger-than-expected reports on manufacturing and housing allay some concerns about the strength of the U.S. economic ... ... [SignOn San Diego - 11/02/2009]
First Reported 10/22/2009 - Updated 10/22/2009 - 1 Documents (in Biology)
Elan focuses on boosting MS drug sales after selling stake to J&J
Kelly Martin, chief executive of Elan, said the Irish drugs group would focus on increasing sales of its multiple sclerosis drug Tysabri, following the sale of a stake... ... [FT.com - Health - 10/22/2009]
In Focus
Network

Blogs

sort by: Date | Relevance
Elan Corporation: Shares Seem Undervalued [Biotech Sector and Stocks Analysis from Seeking ... - 07/10/2009]
Elan Corporation (ELN) About Elan Corporation, plc (Elan) is a neuroscience-based biotechnology company. Its principal research and development, manufacturing ...
J&J lowers price of Elan stake [The Deal.com - 09/15/2009]
Irish drugmaker Elan Corp. plc has revised its agreement with healthcare giant Johnson & Johnson and will get $885 million for an 18.4% stake in the company -- $115 ...
Elan (ELN) drops on Tysabri troubles [BloggingStocks - 06/29/2009]
Filed under: Major movement, Bad news, Options, Technical AnalysisElan Corp (NYSE: ELN - option chain) stock is falling today after Biogen (NASDAQ: BIIB) reported ...
J&J and Elan Cut Deal Price to Resolve Biog... [DealBook - 09/15/2009]
Johnson & Johnson has cut the amount it will pay for its 18.4 percent stake in Irish drugmaker Elan Corp by $115 million to $885 million, Elan confirmed Monday. ...
Elan: Yet another deal rumor -- Bristol eyeing ... [BloggingStocks - 06/01/2009]
Filed under: Deals, Rumors, Bristol-Myers Squibb (BMY)If you've been following Elan Corp. (NYSE: ELN) lately, you've probably come to take any story of a deal, takeover, ...
1 2 3 4 5 6 7 8 9 10 ...

Audio/Video

sort by: Date | Relevance
multiple sclerosis [Mefeedia Video Tag : medicine - 04/01/2009]
multiple sclerosis [Mefeedia Video Tag : medicine - 04/03/2009]
MS Awareness Week [Rep. Russ Carnahan - YouTube Channel - 03/06/2009]
FDA to regulate tobacco [Reuters Video: Top News - 06/12/2009]
Raw Deal [Slate Magazine - 11/11/2009]
1 2 3 4 5 6 7 8 9

  •  
  •  
  •